Print

IAVI C003

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Single Dose of Modified Vaccinia Ankara (MVA) expressing HIV-1 Clade C env/gag-pol and nef-tat fusion genes (ADMVA) Vaccine Administered Intramuscularly to Adult, HIV-Uninfected, Healthy Volunteers who Previously Received Three Doses of a Clade C DNA Vaccine ADVAX e/g + ADVAX p/n-t

Trial Details:

I Completed
Aaron Diamond AIDS Research Center, International AIDS Vaccine Initiative (IAVI), Rockefeller University November 01, 2006
ADMVA env/gag-pol and nef-tat C
ADMVA Viral Vector - Pox
USA 8